高雄長庚肝癌團隊-Kaohsiung Chang Gung Liver Cancer Multidisciplinary Team

03/12/2025

⚡️癌症治療中常聽到"電療"是什麼?⚡️

✍️「電療」，其實就是醫學正式名稱的「放射線治療」，屬於非侵入性的腫瘤治療方式，本院電療又分為「光子治療」 與 「質子治療」，分別比較說明如下：

1️⃣治療原理：
🔆光子治療（傳統X光）：射線具穿透性，殺死腫瘤時也會波及周邊正常肝臟組織。
📍質子治療：具有「布拉格尖峰」物理特性，能量能精準在腫瘤處釋放，大幅減少對正常組織的傷害。特別適合肝功能不佳、腫瘤較大或剩餘肝體積較小的病患。

2️⃣兩者優缺點比較：
🔆光子治療：
👍優點：健保給付（免費或部分配件自費），費用較低；腫瘤控制率”平均”較差、每日治療臥床時間短（約5~10分鐘）。
👎缺點：相對質子治療，腫瘤控制率較差、副作用風險較高。
📍質子治療：
👍優點：腫瘤控制率較高、對正常肝臟傷害低、副作用較少。
👎缺點：需全額自費（本院肝癌依不同狀況，約新台幣35-95萬元）、每日需固定不動時間長（約30~60分鐘）。

3️⃣決策建議：
若想要精準治療效果與較少副作用且預算充足，建議選擇質子治療；若考量經濟負擔或無法長時間平躺，則建議選擇光子治療
⚠️⚠️⚠️最終治療決策請務必與主治醫師共同研議共識。
▫️▫️▫️▫️▫️▫️▫️▫️▫️▫️▫️▫️▫️▫️
⚡️What is " Radiotherapy " in Cancer Treatment?⚡️

✍️Radiotherapy can be further divided into two main types: "Photon Therapy" and "Proton Therapy" .
Here is a comparative explanation of the two:

1️⃣Treatment Principle:
🔆Photon Therapy (Conventional X-Ray): The rays have pe*******on power, meaning they kill the tumor but may also affect surrounding healthy liver tissue.
📍Proton Therapy: It utilizes the physical characteristic of the "Bragg Peak", allowing energy to be precisely released at the tumor site, significantly reducing damage to normal surrounding tissue. Particularly suitable for patients with poor liver function, larger tumors, or smaller remaining liver volume.

2️⃣Comparison of Pros and Cons
🔆Photon Therapy:
👍Pros : Covered by National Health Insurance (free or low-cost); short daily treatment time (approx. 5-10 minutes).
👎Cons ：Relatively lower tumor control rate compared to proton therapy; higher risk of side effects.
📍Proton Therapy
👍Pros : Higher tumor control rate; lower damage to normal liver tissue; fewer side effects.
👎Cons : Requires full out-of-pocket payment (approx. NT$ 700,000 to 900,000); longer daily immobilization time (approx. 30-60 minutes).

3️⃣Decision Guidance：
📍Proton Therapy is recommended if you prioritize precise treatment efficacy and fewer side effects, and have a sufficient budget.
🔆Photon Therapy is recommended if you must consider the financial burden or are unable to lie still for extended periods.
⚠️⚠️⚠️Final Note: The ultimate treatment decision must always be discussed and agreed upon with your treating physician.

11/11/2025

📣📣📣 11/12 颱風特別門診如下📣📣📣

✅胃腸肝膽科
上午：胡琮輝、顏毅豪、蔡明釗
下午：曾柏霖、戴維震、王心明

✅腫瘤科
上午：劉建廷、黃詩喻

✅一般外科
上午：王世和

⏸️門診檢查及門診手術暫停
⏸️門診質子治療及放射治療暫停
⭕️門診化療正常
⚠️請正常上班時間致電該檢查單位調整日期⚠️
⚠️風雨太大請注意安全，可視情況延後回診⚠️

05/11/2025

🌟晚期肝癌不再絕望：溫和而有效的治療選擇🌟

高雄長庚血液腫瘤科陳彥豪醫師表示，結合了免疫治療與抗血管新生藥物的組合療法，為晚期患者提供了更溫和、有效的選擇。
✅ 健保支持，減輕壓力。
✅ 活化自身免疫力，生活品質不中斷。
✅ 請務必： B、C 肝帶原者每六個月定期追蹤，早期發現、積極治療，與醫療團隊一起走向康復之路！

🔗文章來源：Yahoo News🔗
https://share.google/WSfHTU0zmSsOUP6T3

～～～💫 💫 💫 💫 💫 💫～～～
New Hope for Stage III Hepatocellular Carcinoma (HCC): Immunotherapy Combination Covered by National Health Insurance (NHI)

🤷Current Status and Breakthroughs in HCC
HCC, often called the "silent killer," frequently reaches advanced stages before symptoms appear. However, with the advent of immunotherapy, treatment strategies for advanced HCC have significantly improved, shifting the focus to enhancing efficacy and quality of life.

🧬Novel Treatment Regimen
Dr. Chen Yen-Hao of Kaohsiung Chang Gung Memorial Hospital points out that a combination of immunotherapy and anti-angiogenesis (anti-blood vessel growth) drugs has become a crucial option for advanced HCC. This approach works by activating the patient's own immune system to fight cancer cells, resulting in lower side effects compared to traditional therapies.

🔮Clinical Outcome
A patient from Yunlin with Stage III HCC, whose tumor was deemed inoperable due to major vessel invasion, received this treatment after it was covered by the NHI starting in 2023. After two years of therapy, the tumor has significantly shrunk, the condition is well-controlled, and the patient's life has returned to a normal routine.

🧲Multidisciplinary Care
Current treatment emphasizes a multidisciplinary team approach to tailor strategies for each patient. The physician stresses the importance of not giving up after diagnosis and urges high-risk groups, such as those with Hepatitis B or C, to undergo regular check-ups every 6 months.

#陳彥豪醫師
#血液腫瘤科
#肝癌
#免疫治療


(HCC)

【健康醫療網／記者周啟辰報導】過去被稱為「沉默殺手」的肝癌，常在出現明顯症狀時已屬中晚期，讓許多患者一聽到確診就陷入絕望。然而，近年來由於免疫治療的突破性進展，醫界對晚期肝癌的治療策略不再僅止於延長壽...

01/10/2025

🌈健保給付的樂衛瑪（Lenvatinib，Len）與自費的癌思停加癌自禦（Atezolizumab plus Bevacizumab，Ate/Bev）作為不可切除肝細胞癌（uHCC）一線療法的比較成效
🌈Comparing health insurance-reimbursed lenvatinib and self-paid atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma

🖌️郭垣宏醫師 胃腸肝膽科/Dr.Yuan-Hung Kuo, Division of Hepatogastroenterology🖌️

📊研究目的與背景： Len 與 Ate/Bev 均是 uHCC 的一線標準療法。由於在台灣 Len 通常由健保給付，而 Ate/Bev 則需高額自費，因此研究回顧性評估了 346 位患者（Len 組 266 人，Ate/Bev 組 80 人）的治療結果。

1️⃣初始患者特徵差異： 在校正前，選擇自費 Ate/Bev 的患者，其肝功能儲備（Child-Pugh B 級佔比更高）較差，且腫瘤特徵（如腫瘤較大、主門靜脈侵犯）更為晚期，可能存在選擇偏差。
2️⃣安全性比較：Ate/Bev 組的治療相關不良事件（TRAE）發生率顯著低於 Len 組（56.3% vs. 72.3%）。
3️⃣療效主要結論（經 PSM 校正後）： 透過傾向分數匹配（PSM）分析校正基線差異後，兩組在關鍵療效指標上無顯著差異：
4️⃣客觀反應率（ORR）：相似（約 21.9% vs. 21.6%）。
5️⃣無惡化存活期（PFS）：相似（5.1 個月 vs. 6 個月）。
6️⃣總體存活期（OS）：相似（13.3 個月 vs. 14.1 個月）。
7️⃣後續治療：Ate/Bev 組在停止一線治療後，接受後續全身性治療的比例高於 Len 組，且多數（90.9%）轉為接受酪胺酸激酶抑制劑（TKI，如 Len）治療。
⭕️總結： 儘管患者的疾病嚴重度與健保給付狀態不同，但經校正後，健保給付的 Len 與自費的 Ate/Bev 作為 uHCC 一線治療，展現出相似的療效與安全性。這強調了臨床上根據患者具體情況進行個體化治療決策的重要性。

📊This study, published in the American Journal of Cancer Research, aimed to compare the real-world effectiveness and safety of National Health Insurance (NHI)-reimbursed Lenvatinib (Len) versus self-paid Atezolizumab plus Bevacizumab (Ate/Bev) as first-line treatments for patients with unresectable hepatocellular carcinoma (uHCC).
Key Findings
1️⃣Initial Baseline Differences: Patients who opted for self-paid Ate/Bev initially presented with worse liver function (higher proportion of Child-Pugh class B) and more advanced tumor characteristics (e.g., larger tumors, major portal vein invasion), suggesting a potential selection bias.
2️⃣Safety Profile: The incidence of treatment-related adverse events (TRAE) was significantly lower in the Ate/Bev group compared to the Len group (56.3% vs. 72.3%).
3️⃣Main Efficacy Conclusion (After PSM): After Propensity Score Matching (PSM) was used to adjust for baseline differences, both treatment regimens demonstrated no statistically significant difference in key efficacy outcomes:
4️⃣Objective Response Rate (ORR): Comparable (\approx 21.9\% vs. 21.6\%).
5️⃣Progression-Free Survival (PFS): Similar (5.1 months vs. 6 months).
6️⃣Overall Survival (OS): Similar (13.3 months vs. 14.1 months).
⭕️Conclusion: Despite initial patient characteristic disparities and different reimbursement statuses, the NHI-reimbursed Len and self-paid Ate/Bev provided comparable efficacy and safety profiles. The study highlights the importance of individualized treatment decisions based on patient-specific factors.

✅Am J Cancer Res. 2025 Feb 15;15(2):811–823. doi: 10.62347/BYIE2654

🔗 https://pmc.ncbi.nlm.nih.gov/articles/PMC11897613/

#通訊作者王景弘
#第一作者郭垣宏
#肝癌
#胃腸肝膽科

Atezolizumab plus bevacizumab (Ate/Bev) and lenvatinib (Len) are first-line therapies for unresectable hepatocellular carcinoma (uHCC). However, Ate/Bev’s high cost limits its common use in real-life practice, while Len is usually covered by ...

03/09/2025

🔥🔥主題：破裂性肝癌的處置

⭕️臨床上肝癌破裂的案例並不罕見，通常會以突發性的劇烈腹痛，低血容性休克(暈眩、眼前發黑)或是腹脹來表現。被診斷罹患肝癌的患者一旦有以上的症狀，都應該盡快至最近最近的醫院急診室就醫，可藉由超音波或是電腦斷層來確定診斷，後續的緊急處置需視病患的臨床表現來決定。

1️⃣生命跡象穩定: 可以先採保守治療，若有貧血，則給予紅血球濃縮液輸注。
2️⃣生命跡象不穩定: 給予紅血球濃縮液輸注，盡快安排血管攝影及血管栓塞術治療。若止血成功，病患的血壓、心跳會回到穩定狀態。
肝癌破裂是一個影響肝癌治療預後的因素，後續產生腹腔內蔓延的機會也會提高。然而一旦止血成功，後續的治療可根據病患的身體狀況、肝臟功能及腫瘤的狀況來選擇合適的治療，包括手術切除的機會，仍然有機會獲得不錯的治療效果。

▶️以下分享一個案例:
疫情期間，一位73歲的婆婆，因腹痛被送到急診，有貧血狀況，電腦斷層發現右側肝臟有一顆13公分的腫瘤，且腫瘤周圍有血水及顯影劑外滲的狀況，懷疑腫瘤破裂出血，急診室立即安排血管栓塞術治療。止血後生命徵象回復穩定。轉入外科評估是否可手術切除腫瘤。
然而栓塞造成腫瘤大範圍的壞死並形成肝膿瘍，治療感染期間又併發了新冠肺炎感染，總算在置放了肝膿瘍引流管，配合抗生素及抗病毒藥物的治療後，身體狀況逐漸穩定下來。此外，婆婆本身的肝臟功能還不錯，終於在住院一個半月後可以接受右側肝臟切除手術。術後恢復順利，病理報告顯示栓塞後腫瘤100%壞死。持續追蹤至今，目前狀況穩定且無腫瘤復發的情況。

#ㄧ般外科
#李韋鋒醫師

12/08/2025

📣📣📣 8/13 門診如下📣📣📣

✅胃腸肝膽科
上午：胡琮輝、顏毅豪、蔡明釗
下午：曾柏霖、戴維震、王心明

✅腫瘤科
上午：劉建廷、黃詩喻

✅一般外科
上午：王世和

⏸️門診檢查及門診手術暫停
⏸️門診質子治療及放射治療暫停
⭕️門診化療正常
⚠️請正常上班時間致電該檢查單位調整日期⚠️
⚠️風雨太大請注意安全，可視情況延後回診⚠️

06/08/2025

🔥🔥主題：晚期肝癌治療契機，釔-90微球放射治療

🔗🔗https://cloudhd.cgmh.org.tw/navigate/a/ #/s/3E791CFAB6DF41289C4197D0241740496BL

#余俊彥醫師主講

28/07/2025

📣📣📣7/29 門診如下📣📣📣

✅胃腸肝膽科
上午：邱逸群、吳鎮琨、王景弘（癌症中心）
下午：郭仲謀、紀廣明、姚志謙

✅腫瘤科
上午：李劭軒、陳彥豪

✅一般外科
上午：劉毓寅
下午：劉毓寅

⏸️門診檢查及門診手術暫停
⏸️門診質子治療及放射治療暫停
⚠️請正常上班時間致電檢查單位調整日期⚠️
⚠️風雨太大請注意安全，可視情況延後回診⚠️

06/07/2025

📣📣📣7/7 颱風🌀門診📣📣📣

✅胃腸肝膽科
上午：盧勝男、洪肇宏、張國欽、黃寳源
下午：趙景華、蘇輝明、胡琮輝（癌症中心門診）

✅血液腫瘤科
上午：陳彥豪 、吳佳哲

✅一般外科
上午：王世和
下午：葉承熙

⏸️門診檢查及門診手術暫停
⏸️門診質子治療及放射治療暫停
⚠️請正常上班時間致電該檢查單位調整日期⚠️
⚠️風雨太大請注意安全，可視情況延後回診⚠️

02/07/2025

🤵‍♀️自2023年8月起，健保開始給付免疫治療合併抗血管新生標靶藥物（atezolizumab + bevacizumab ）於肝癌中晚期病人; 2025年2月1日 起，雙免疫藥物(Tremelimumab+Durvalumab) 也已納入台灣健保給付範圍，免疫治療逐漸成為中晚期肝癌病人的重要療法，不僅大大增加個案存活率也提升個案生活品質，現在我們來聊聊免疫治療副作用是什麼? 遇到了怎麼辦?

🤵‍♀️免疫療法的運作是通過「喚醒」身體的免疫系統來對抗癌症，但有時這個被激活的免疫系統也可能錯誤地攻擊健康細胞，導致我們所稱的免疫相關副作用。

⚠️這些常見副作用有：
• 皮膚：皮疹、搔癢、乾燥。
• 腸胃：腹瀉、胃痛、噁心。
• 精力 ：極度疲勞。
•腎臟：蛋白尿。
• 肝臟：感覺疲倦、尿液顏色變深、皮膚或眼睛變黃（黃疸）。
• 腺體（甲狀腺等）： 感覺過熱/過冷、體重變化、情緒變化。
• 肺部： 新出現的咳嗽或呼吸急促。
• 關節/肌肉： 酸痛、疼痛、僵硬。

‼️何時應聯絡醫療團隊或盡早回門(急)診：
• 發燒（體溫超過 38°C）
• 嚴重腹瀉（大量稀便，或帶有血絲/黏液）
• 新的或惡化的呼吸急促或咳嗽
• 嚴重胃痛
• 皮膚或眼睛變黃（黃疸）
• 嚴重頭痛或視力改變
• 嚴重皮疹、起水泡或皮膚脫皮
• 肌肉無力導致難以移動或行走

🔆我們如何處理副作用：
• 及早告知我們！ 您越早報告症狀，我們就越容易處理。
• 監測： 我們會定期檢查（驗血、身體檢查）以發現問題。
• 藥物： 醫師會評估時機，必要時使用類固醇來平息您的免疫系統。
• 暫停治療： 有時我們可能會暫時停止您的免疫治療，直到副作用好轉。這是正常情況，有助於確保您的安全。
• 轉診專科醫生： 對於嚴重的副作用，我們可能會將您轉診給該領域的專科醫生。

✅日常自我照護小撇步：
• 保持水分： 多喝水。
• 均衡飲食： 盡量均衡飲食。如果腸胃不適，請選擇清淡的食物。
• 休息與活動： 休息與輕度活動並行，以幫助緩解疲勞。
• 保護皮膚： 使用保濕霜和防曬乳（SPF 30+）。
• 記錄症狀： 寫下任何症狀、何時開始以及嚴重程度。這有助於我們了解情況。
💓免疫治療副作用不可怕，請隨時向我們提出任何問題。您的參與對您的安全和成功治療至關重要💗

🤵‍♀️ Since August 2023, National Health Insurance (NHI) has covered immunotherapy combined with anti-angiogenic targeted therapy (atezolizumab + bevacizumab) for patients with intermediate to advanced liver cancer. Starting February 1, 2025, dual immunotherapy (Tremelimumab + Durvalumab) has also been included in Taiwan's NHI coverage. Immunotherapy is gradually becoming an important treatment for patients with intermediate to advanced liver cancer, not only significantly increasing survival rates but also improving the quality of life for individuals. Now, let's discuss what immunotherapy side effects are and what to do if you experience them.

🤵‍♀️ Immunotherapy works by "waking up" the body's immune system to fight cancer. However, sometimes this activated immune system can mistakenly attack healthy cells, leading to what we call immune-related side effects.

⚠️ Common side effects include:

• Skin: Rash, itching, dryness.
• Gastrointestinal: Diarrhea, stomach pain, nausea.
• Energy: Extreme fatigue.
• Kidney: Proteinuria.
• Liver: Feeling tired, dark urine, yellowing of skin or eyes (jaundice).
• Glands (e.g., Thyroid): Feeling too hot/cold, weight changes, mood changes.
• Lungs: New or worsening cough or shortness of breath.
• Joints/Muscles: Aches, pain, stiffness.

‼️ When to contact your medical team or seek early (emergency) medical attention:

• Fever (body temperature over 38°C)
• Severe diarrhea (large amount of loose stools, or with blood/mucus)
• New or worsening shortness of breath or cough
• Severe stomach pain
• Yellowing of skin or eyes (jaundice)
• Severe headache or vision changes
• Severe rash, blistering, or peeling skin
• Muscle weakness leading to difficulty moving or walking

🔆 How we manage side effects:

• Tell us early! The sooner you report symptoms, the easier it is for us to manage them.
• Monitoring: We will conduct regular checks (blood tests, physical exams) to detect issues.
• Medication: Your doctor will assess the timing and, if necessary, use steroids to calm your immune system.
• Treatment Pause: Sometimes we may temporarily stop your immunotherapy until side effects improve. This is normal and helps ensure your safety.
• Referral to Specialists: For severe side effects, we may refer you to a specialist in that field.

✅ Daily Self-Care Tips:

• Stay Hydrated: Drink plenty of water.
• Balanced Diet: Try to eat a balanced diet. If you have stomach upset, choose bland foods.
• Rest and Activity: Balance rest with light activity to help alleviate fatigue.
• Protect Your Skin: Use moisturizer and sunscreen (SPF 30+).
• Record Symptoms: Write down any symptoms, when they started, and their severity. This helps us understand your condition.

💓 Immunotherapy side effects are not scary. Please feel free to ask us any questions at any time. Your participation is crucial for your safety and successful treatment. 💗

11/06/2025

🧲質子治療─早期肝癌治療的替代方案 [Proton Therapy – An Alternative Option for Early-Stage Hepatocellular Carcinoma]🧲

🖌️ 放射腫瘤科 鄭任祐醫師/ Radiation Oncology Dr. Jen Yu Cheng

1️⃣早期肝癌的標準治療方式通常為手術切除或射頻燒灼（RFA），這兩種方式在多數情況下都有不錯的療效。不過，隨著醫療科技的進步，現今的放射治療也展現了優秀的成果。最新的臨床研究顯示，現代精準的放射治療，其效果並不亞於傳統的一線治療¹²。
2️⃣質子治療是新一代的放射治療技術，特別適合用來治療肝臟腫瘤。相較於傳統的光子放射治療，質子治療可以更精準地集中能量於腫瘤上，進一步降低對健康肝臟組織的傷害，減少副作用，同時提升病患的存活率³⁴。此外，質子治療屬於非侵入性的治療，不需要開刀，也不需麻醉，對病患而言更為安全且舒適。
3️⃣目前在高雄長庚醫院，對於早期肝癌的病患，仍會以手術或RFA為第一優先。不過，若腫瘤位置不適合進行這些治療，或病人因健康因素、年齡或個人信仰而不適合接受侵入性治療時，質子治療便是一項理想的替代選擇。

♥️案例分享♥️
65歲的李先生為慢性B型肝炎患者，長期在門診定期追蹤。2023年底的檢查中意外發現肝臟有一顆4.5公分的腫瘤，診斷為早期肝癌。雖然醫療團隊建議手術切除，但考量個人生涯及宗教信仰，李先生在諮詢後選擇接受質子治療。整個治療過程中無不適，並在治療後一年追蹤的核磁共振檢查中發現，腫瘤已完全壞死，無任何殘留或復發跡象。（見下圖）

🧲Proton Therapy – An Alternative Option for Early-Stage Hepatocellular Carcinoma🧲

1️⃣For early-stage liver cancer, the standard treatments are surgical resection or radiofrequency ablation (RFA). These methods are generally effective and well-established. However, recent advances in radiation technology have introduced new possibilities. Clinical trials now demonstrate that modern, precise radiation therapies can be equally effective as RFA¹².
2️⃣Proton therapy is one of the most advanced forms of radiation therapy, offering unique advantages in treating liver tumors. Compared to conventional photon-based radiation, proton therapy focuses radiation on the tumor, minimizing damage to surrounding healthy liver tissue, which may reduce side effects and improve patient survival³⁴. Additionally, it is a non-invasive treatment that does not require surgery or anesthesia, offering a safer and more comfortable experience for many patients.
3️⃣At Kaohsiung Chang Gung Memorial Hospital, we still recommend surgery or RFA as first-line treatments for early-stage liver cancer. However, if the tumor's location makes these treatments difficult or if the patient cannot undergo invasive procedures due to medical conditions, age, or personal beliefs, proton therapy becomes a valuable alternative.

♥️Patient Story♥️
Mr. Lee, a 65-year-old with chronic hepatitis B, was undergoing routine check-ups when a 4.5 cm tumor was discovered in his liver in late 2023. Diagnosed with early-stage hepatocellular carcinoma, surgery was initially recommended. However, due to personal career plans and religious beliefs, Mr. Lee chose proton therapy as an alternative. The entire treatment was well-tolerated with no side effects. One year after treatment, MRI scans confirmed complete tumor necrosis, with no signs of recurrence.

🗓️References🗓️
1. J Hepatol . 2021 Mar;74(3):603-612. doi: 10.1016/j.jhep.2020.09.026.
2. J Clin Oncol . 2025 Mar 20;43(9):1073-1082. doi: 10.1200/JCO-24-01532.
3. Radiat Oncol . 2020 Jun 30;15(1):159. doi: 10.1186/s13014-020-01605-4.
4. Int J Radiat Oncol Biol Phys . 2019 Sep 1;105(1):64-72. doi: 10.1016/j.ijrobp.2019.01.076.

#放射腫瘤科
#鄭任祐醫師
#質子治療
#肝癌

14/05/2025

🧲肝癌免疫治療的逆轉勝🧲
🧲Turnaround victory of immunotherapy for hepatocellular carcinoma🧲

🖌️第一作者 黃淳郁醫師/ First author Mikee Elaine Uy Wee
🖌️通訊作者 洪肇宏醫師/ Correspondence author Chao Hung Hung

✍️假性進展是對免疫治療的一種非典型反應模式，其特徵是最初腫瘤增大或出現新的病變，隨後腫瘤消退。雖然這種現象已在多種實體腫瘤中觀察到，但它在肝癌的發生率很低且尚不明確，給診斷和治療帶來了挑戰。
💁‍♀️我們報告一名61歲女性患有慢性B型肝炎相關晚期肝癌的病例。經過多次治療後，她開始接受癌自癒與癌思停合併治療。經過四個治療週期後，影像學發現腫瘤增大並出現新的小病變顯示病情進展，但她的血清甲型胎兒蛋白濃度從45,598 ng/mL降至23,719 ng/mL，且沒有臨床惡化，因此我們建議繼續治療。然而在八個和十二週期後的影像學檢查顯示腫瘤明顯消退且甲型胎兒蛋白完全正常（